Abstract
Purpose of the studyHypertension is one of the most common comorbidities in COVID-19 pneumonia. However, whether it is an independent factor on the severity and mortality of COVID-19 has not...
Highlights
As of 27 April 2021, a cumulative total of 147 539 302 cases and 3116 444 deaths have been caused by COVID-19 since the start of the outbreak.[1]
There were no significant differences between the two subgroups underlying comorbidities, including cancer (p=0.327), chronic kidney disease (p=0.163), chronic kidney disease (p=0.848), asthma (p=0.280), heart failure (p=0.280), arrhythmia (p=0.059), bronchiectasis (p=0.534), systemic lupus erythematosus (p=0.513), diabetes (p=0.007), coronary heart disease (p=0.000) and stroke (p=0.000), which demonstrated that hypertensive patients had a higher comorbidity rate than non-hypertensive patients with glucolipid metabolic disease, which is consistent with the results of previous studies.[3 7]
Our results showed that hypertension was associated with significantly increased mortality, and a similar association was observed in different subgroups after propensity score matching (PSM) removed
Summary
As of 27 April 2021, a cumulative total of 147 539 302 cases and 3116 444 deaths have been caused by COVID-19 since the start of the outbreak.[1] its mortality rate has been decreasing by 3% per week until now, its incidence rate continues to increase by 1% in the number of cases per week. COVID-19 poses a great challenge to public health and the global economy. It was estimated that almost 1.39 billion adults worldwide were hypertensive.[2] Hypertension causes a variety of diseases that greatly increase the mortality rate in the population. Many patients with COVID-19 are hypertensive, which has caused a lot of discussion on the treatment of hypertensive patients. The use of angiotensin II receptor blocker (ARB)/ACE inhibitors has become a hot topic in patients with COVID-19
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
